Yes the quality of scientific research in this area has been rather bad with rushes to publish and ineffective peer review. Drs. Paul Marik and Pierre Kory recently updated their meta analysis to remove the retracted Elgazzar paper, and still found a significant effect. I'm not endorsing their letter, just pointing out that it exists and isn't mentioned in this Nature article. https://journals.lww.com/americantherape…
Looking at the two papers (original, and updated) they only removed the Elgazzer paper but not the contested Shakhsi Niaee also mentioned in the Nature article. This is noteworthy because it's also the only other RCT to show strong effect on mortality (see Fig3 in the two papers). Original Marik, Kory paper Fig3 is here: https://pubmed.ncbi.nlm.nih.gov/34375047/#&gid=article-figur... Also, the Nature article is conce…
https://www.covid19treatmentguidelines.nih.gov/
In addition to mortality it probably makes sense to look at other endpoints such as patient reported symptoms, RT PCR test cycle count, and time to hospital discharge. Those should allow us to tell if there is a real effect (or not) with smaller subject groups.